Sign up to access historical data
Similar companies
| Company | Transaction Value | |
|---|---|---|
 |
Abbott LaboratoriesABT |
$1.73B |
 |
Tempus AITEM |
-$136B |
 |
SolventumSOLV |
-$1.88B |
 |
Cosmos HealthCOSM |
$113M |
 |
TeleflexTFX |
$7.4M |
Insider Transactions
| Name | Transaction Date | Sold / Bought | Shares | Price | Value |
|---|---|---|---|---|---|
| Swartz Allison | Mar 4, 2026 | Sell | 599 | $17.54 | $11,000 |
| Swartz Allison | Mar 3, 2026 | Sell | 4,157 | $17.4 | $72,000 |
| Swartz Allison | Mar 3, 2026 | Sell | 500 | $17.396 | $8,700 |
| Swartz Allison | Mar 2, 2026 | Sell | 2,199 | $17.27 | $38,000 |
| Livingston Mark S. | Dec 11, 2025 | Sell | 459 | $25.5 | $12,000 |
| Swartz Allison | Dec 4, 2025 | Sell | 530 | $24.59 | $13,000 |
| Livingston Mark S. | Dec 2, 2025 | Sell | 213 | $25.5 | $5,400 |
| Swartz Allison | Nov 28, 2025 | Sell | 2,398 | $26.87 | $64,000 |
| Livingston Mark S. | Nov 17, 2025 | Sell | 21,303 | $25.5 | $540,000 |
| Anevski Peter | Nov 13, 2025 | Buy | 79,500 | $24.288 | $1.9M |
| Swartz Allison | Sep 4, 2025 | Sell | 599 | $23.53 | $14,000 |
| Swartz Allison | Aug 28, 2025 | Sell | 2,398 | $22.96 | $55,000 |
| GORDON KEVIN K | Aug 11, 2025 | Sell | 2,500 | $22.035 | $55,000 |
| Scott Cheryl | Jun 11, 2025 | Sell | 2,675 | $22.07 | $59,000 |
| Schlanger David J | Dec 26, 2024 | Buy | 150,000 | $14.6822 | $2.2M |
| Anevski Peter | Dec 23, 2024 | Buy | 209,500 | $14.4825 | $3M |
| Payson Norman | Nov 23, 2024 | Sell | 200 | $56.29 | $11,000 |
| Sturmer Michael E | Jul 16, 2024 | Sell | 9,030 | $30 | $270,000 |
| Scott Cheryl | Jun 28, 2024 | Sell | 1,462 | $28.39 | $42,000 |
FAQ - Insider Transactions
The most recent insider transaction for Progyny was conducted by Swartz Allison, who sold 599 shares on March 4, 2026 at a price of $17.54 per share.
Anevski Peter has bought the most PGNY stock in the last 2 years, with a total value of $5M.
Livingston Mark S. has sold the most PGNY stock in the last 2 years, with a total value of $560,000.
According to our estimates, the total value of insider transactions for Progyny in the last 2 years is positive, amounting to $5.9M. This indicates that insiders have predominantly bought shares, showcasing their confidence in the company's future prospects.
Over the last 2 years, insider transactions for Progyny have largely consisted of selling shares, which could suggest various personal or financial motivations among insiders. The higher number of sales might require investors to investigate further, considering insiders might have insights or reasons not immediately apparent to the public.
Monitoring insider trading activity is important because it provides insights into the confidence levels of a company's insiders, such as executives and directors, regarding the company's future prospects. Insider buying can signal optimism, suggesting the stock may be undervalued, while insider selling might raise questions about the stock's upcoming performance. However, it's essential to consider that sales can also occur for personal financial reasons. Insider trading activity is a valuable indicator that, when combined with other data, can help inform investment decisions.
